NRF2 / xCT ‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer
Cancer Science · 2026
DOI: 10.1111/cas.70437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Jiaxing Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Amino Acid Transport System ASC, Prostatic Neoplasms, Apoptosis. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Glutamine supports biosynthesis and redox homeostasis in cancer cells. The glutamine transporter ASCT2 is highly expressed in prostate cancer and is associated with higher Gleason grade. Although ASCT2 inhibition induces reactive oxygen species (ROS) accumulation and apoptosis, cancer cells may activate antioxidant adaptive mechanisms that limit therapeutic efficacy. Here, we identified an NRF2/xCT‐dependent redox‐adaptive response following ASCT2 inhibition in prostate cancer. Mechanistically, ASCT2 inhibition induced ROS accumulation, promoted nuclear translocation of NRF2, and upregulated xCT together with other NRF2‐associated antioxidant genes. Functional redox analysis showed that ASCT2 inhibition reduced glutathione‐dependent redox capacity, whereas combined ASCT2 and xCT inhibition further increased GSSG accumulation and markedly decreased GSH levels and the GSH/GSSG ratio. These fin\dings were further validated in C4‐2 cells as an additional prostate cancer model. Cell death discrimination assays showed that combined ASCT2 and xCT inhibition induced lipid peroxidation that was partially rescued by ferrostatin‐1, whereas z‐VAD produced a stronger rescue effect and Annexin V/PI staining confirmed prominent apoptotic cell death. In castrated 22Rv1 xenograft models, combined treatment with V‐9302 and erastin produced the strongest inhibition of tumor growth without significant body weight loss during treatment. Collectively, these findings demonstrate that NRF2/xCT‐mediated residual glutathione redox buffering functions as an adaptive survival mechanism following ASCT2 inhibition and provide a mechanistic rationale for combined targeting of ASCT2 and xCT to overcome redox‐adaptive resistance in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Molecular Oncology, Chiba University Graduate School of Medicine, Chiba, Japan.
ORCID-Profile: Jiaxing Wei, Xue Zhao, Tomokazu Sazuka, Shinichi Sakamoto
Förderung
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
Zitieren
APA
Wei, J., Yamada, Y., Tamura, T., Sugiura, M., Zhao, X., Ni, M., Aierken, A., Sazuka, T., Imamura, Y., & Sakamoto, S. (2026). NRF2 / xCT ‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer. Cancer Science. https://doi.org/10.1111/cas.70437
Vancouver
Wei J, Yamada Y, Tamura T, Sugiura M, Zhao X, Ni M, et al. NRF2 / xCT ‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer. Cancer Science. 2026. doi:10.1111/cas.70437
BibTeX
@article{Wei2026,
author = {Wei, Jiaxing and Yamada, Yasutaka and Tamura, Takaaki and Sugiura, Masahiro and Zhao, Xue and Ni, Meng and Aierken, Adilan and Sazuka, Tomokazu and Imamura, Yusuke and Sakamoto, Shinichi},
title = {NRF2 / xCT ‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70437}
}
EUVIMED